查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093385

藥品活性成分（API）CDMO市場－全球市場預測（2026-2032年）

Active Pharmaceutical Ingredients CDMO Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，活性藥物成分 (API) 的 CDMO 市場將成長至 2,211.5 億美元，複合年成長率為 9.70%。

主要市場統計數據
基準年 2025 1156.6億美元
預計年份：2026年 1266.1億美元
預測年份 2032 2211.5億美元
複合年成長率 (%) 9.70%

隨著製藥公司尋求在原料藥開發、規模化生產、製程驗證和商業化生產方面可靠、合規且技術先進的合作夥伴，活性藥物成分（API）的合約研發生產（CDMO）服務正日益成為藥物供應策略的核心。這項需求源自於小分子API、高活性化合物、胜肽和寡核苷酸相關化學物質、受管制物質以及特殊治療藥物的日益複雜化，這些藥物需要先進的安全防護措施、嚴格的分析以及基於品質的設計（QbD）。同時，監管機構持續重視資料完整性、雜質控制、亞硝胺風險評估、良好生產規範（GMP）合規性以及強大的供應鏈可追溯性，這使得與經驗豐富的CDMO合作夥伴在整個藥物生命週期中的合作變得愈發重要。

此外，API CDMO產業的趨勢也受到專利到期、學名藥和專科藥物研發管線擴張、生產回流討論、雙重採購策略以及對強大生產網路的需求等因素的影響。委託企業優先考慮那些擁有強大的化學開發能力、法規遵循、環境、健康和安全（EHS）體系，以及能夠高效地從臨床階段生產過渡到檢驗的商業化供應的合作夥伴。因此，活性藥物成分（API）CDMO供應商正在從單純的契約製造製造商轉型為支援製劑完整性、法規文件、生命週期管理和持續改進的策略合作夥伴。

對 API CDMO 業務進行變革性重組。

活性藥物成分（API）合約研發生產（CDMO）產業正經歷變革，其驅動力來自供應鏈韌性的提升、日益嚴格的監管、技術的現代化以及治療重點的轉變。在評估CDMO時，製藥公司越來越重視的不僅是產能和成本效益，還包括技術深度、品質文化、永續性以及安全管理複雜化學反應的能力。該產業正朝著一體化的研發生產模式發展，將合成路線探索、製程最佳化、分析方法開發、雜質分析、放大工程和法規遵從等環節整合到一個協調的品質系統中。

人工智慧（AI）對原料藥合約研發生產機構的累積影響

人工智慧 (AI) 透過增強製程開發、分析工作流程、品質保證和供應鏈中的決策能力，對活性藥物成分 (API) CDMO 的整個價值鏈產生累積影響。 AI 工具能夠幫助開發團隊加深對製程的理解，並透過輔助合成路線選擇、反應最佳化、雜質預測、結晶建模和程式參數分析來縮短實驗週期。在 API 生產中，將機器學習引入經過檢驗的資料管治框架可以增強偏差檢測、設備監控、預測性維護和批次趨勢分析。

API CDMO生態系的關鍵區域洞察

亞太地區憑藉其成熟的化學合成能力、大規模的供應商基礎、技術人才儲備以及在學名藥和創新藥生產中的顯著參與，在活性藥物成分（API）合約研發生產（CDMO）生態系統中扮演著至關重要的角色。中國和印度仍然是主要的API生產中心，而日本、韓國、澳洲和東南亞國協則透過高品質的生產製造、專業知識、臨床供給能力和區域多元化策略做出貢獻。監管現代化、對高活性物質處理的投資以及對品質系統日益重視進一步鞏固了該地區的地位，但相關企業仍需持續評估地緣政治風險、環境合規性和供應鏈透明度。

影響API CDMO策略的關鍵集團洞察

儘管北約成員國並非醫藥貿易集團，但許多國家都將基本藥物、關鍵原料和醫療保健系統的安全供應鏈放在首位，這使其在活性藥物原料藥（API）的合約研發生產（CDMO）戰略中的重要性日益凸顯。這種對韌性的重視，促使人們關注可靠的供應商網路、地理分散的採購方式，以及在國內或聯盟區域內生產對公共衛生和緊急準備至關重要的API。

來自主要國家關於活性藥物成分（API）CDMO的見解

美國是活性藥物成分（API）CDMO服務的主要需求中心，這得益於其強大的生物製藥研發管線、嚴格的監管要求以及對國內生產韌性的日益重視。加拿大透過合規的生產能力、臨床開發支援以及對生命科學領域的投資做出貢獻，而墨西哥則憑藉近岸外包優勢、接近性美國市場以及不斷擴大的藥品生產能力，其重要性日益提升。巴西仍然是拉丁美洲最大的藥品市場，在區域生產、公共衛生採購和學名藥供應方面發揮著至關重要的作用。

為原料藥CDMO產業的領導者提供實用建議。

產業領導者應優先考慮具有韌性、合規性和技術驅動的原料藥合約研發生產（API CDMO）策略。申辦方應根據GMP檢查歷史、資料完整性成熟度、製程化學專業知識、隔離能力、供應連續性計劃、環境、健康和安全（EHS）績效以及監管文件的合格來評估合作夥伴的資格。對於關鍵原料藥、高風險原料以及供應商選擇有限的產品，應策略性地採用雙重採購和地理多元化策略。

API CDMO 分析的調查方法

分析活性藥物成分（API）合約研發生產企業（CDMO）產業格局的調查方法應結合檢驗的二手研究、監管資訊、產業文件和專家檢驗。關鍵資訊來源包括公開的監管指南、GMP檢查框架、藥典標準、政府貿易和衛生機構出版刊物、同行評審的科學文獻、專利和在研項目指標，以及有關生產能力、品質系統和技術應用方面的行業資訊披露。

結論：API CDMO 的策略展望

隨著製藥企業在複雜的研發管線、供應鏈風險和不斷變化的監管預期中尋求應對，原料藥（API）原料藥生產（CDMO）產業正變得更加戰略化、技術主導，並且對合規性也日益重視。該行業的未來發展方向將取決於其技術專長、地理適應能力、數位化成熟度以及從早期研發到商業化生產始終如一地提供高品質產品的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥物活性成分（API）CDMO市場：依分子類型分類

  • 合成原料藥
  • 生技原料藥
    • 蛋白質
    • mAbs
    • 胜肽
  • 進階 API

第8章：藥品活性成分（API）CDMO市場：依API類別分類

  • 非專利API
  • 品牌 API

第9章：藥品活性成分（API）CDMO市場：依生產技術分類

  • 生物催化劑
  • 發酵
  • 合成化學

第10章：藥品活性成分（API）CDMO市場：依服務組合分類

  • 製程開發
    • 尋找並選擇製造路線
    • 流程最佳化
    • 規模擴大和技術轉移
  • 客製合成
    • 藥物發現階段
    • 非GMP規模
    • GMP規模
  • 臨床生產
    • 第一階段臨床試驗的供應
    • 二期臨床試驗的供應
    • 用於 III 期臨床試驗的供應
  • 商業生產
    • 專用線路
    • 多功能生產線
  • 分析和品質服務
    • 分析方法的開發
    • 驗證和轉移
    • 穩定性測試
    • 船舶檢驗
  • 支援法規和文件編制
    • CMC申請文件準備
    • 支持監管申請
    • 審計和檢查支持

第11章：醫藥活性成分（API）CDMO市場：依研發階段分類

  • 臨床前開發
  • 臨床階段
  • 商業原料藥生產

第12章：藥物活性成分（API）CDMO市場：依治療應用分類

  • 腫瘤學
    • 固體癌
    • 骨髓惡性腫瘤
  • 心血管系統
    • 高血壓
    • 血脂異常症
    • 血栓症
  • 中樞神經系統
    • 精神疾病
    • 神經病變
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
    • 黴菌感染疾病
    • 寄生蟲感染疾病
  • 代謝/內分泌
    • 糖尿病
    • 肥胖
    • 甲狀腺疾病
  • 呼吸系統
    • 氣喘
    • 慢性阻塞性肺病
  • 自體免疫/發炎性疾病
    • 風濕病學
    • 皮膚自體免疫疾病
    • 消化器官系統自體免疫疾病
  • 消化器官系統
    • 與酸相關的疾病
    • 運動功能障礙
    • 發炎性腸道疾病
  • 皮膚科
    • 銀屑病
    • 痤瘡和酒糟
  • 眼科
    • 青光眼
    • 視網膜疾病

第13章：醫藥活性成分（API）CDMO市場：依最終用戶分類

  • 製藥公司
  • 生技公司
  • 學名藥生產商

第14章：藥品活性成分（API）CDMO市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 非洲
  • 拉丁美洲
  • 中東

第15章：醫藥活性成分（API）CDMO市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第16章：藥品活性成分（API）CDMO市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 義大利
  • 韓國
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • 5N Plus Inc.
  • AR Life Sciences Pvt. Ltd.
  • AbbVie Inc.
  • abcr GmbH
  • Aurobindo Pharma Limited
  • BASF SE
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc. by Novo Holdings A/S
  • Cipla Limited
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Evonik Industries AG
  • IOL Chemicals and Pharmaceuticals Limited
  • Jungbunzlauer Suisse AG
  • Lonza Group Ltd.
  • Lupin Limited
  • Merck KGaA
  • Minafin Group
  • Novartis AG
  • Olon SpA
  • Pfizer Inc.
  • Piramal Group
  • PMC Group, Inc.
  • Polpharma SA
  • Recipharm AB
  • Samsung Biologics
  • SEQENS
  • Siegfried AG
  • Sterling Pharma Solutions Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc
  • Tiefenbacher API+Ingredients GmbH & Co. KG
  • WuXi STA
Product Code: MRR-575EAC9DD1AE

The Active Pharmaceutical Ingredients CDMO Market is projected to grow by USD 221.15 billion at a CAGR of 9.70% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 115.66 billion
Estimated Year [2026] USD 126.61 billion
Forecast Year [2032] USD 221.15 billion
CAGR (%) 9.70%

Active Pharmaceutical Ingredients CDMO services have become central to pharmaceutical supply strategy as drug developers seek reliable, compliant, and technically advanced partners for API development, scale-up, process validation, and commercial manufacturing. Demand is shaped by the rising complexity of small-molecule APIs, highly potent compounds, peptide and oligonucleotide-related chemistries, controlled substances, and specialty therapeutics that require advanced containment, analytical rigor, and quality-by-design execution. At the same time, regulatory authorities continue to emphasize data integrity, impurity control, nitrosamine risk assessment, good manufacturing practice compliance, and robust supply chain traceability, making experienced CDMO partnerships increasingly important across the drug lifecycle.

The API CDMO landscape is also influenced by patent expirations, expanding generic and specialty medicine pipelines, reshoring discussions, dual-sourcing strategies, and the need for resilient manufacturing networks. Sponsors are prioritizing partners with strong chemistry development capabilities, regulatory inspection readiness, environmental health and safety systems, and the ability to transition efficiently from clinical-stage production to validated commercial supply. As a result, Active Pharmaceutical Ingredients CDMO providers are evolving from transactional manufacturers into strategic collaborators that support formulation alignment, regulatory documentation, lifecycle management, and continuous improvement.

Transformative Shifts Reshaping API CDMO Operations

The Active Pharmaceutical Ingredients CDMO sector is undergoing transformative shifts driven by supply chain resilience, regulatory tightening, technology modernization, and changing therapeutic priorities. Pharmaceutical sponsors are increasingly evaluating CDMOs not only on capacity and cost efficiency but also on technical depth, quality culture, sustainability practices, and the ability to manage complex chemistry safely. The industry is moving toward integrated development and manufacturing models that combine route scouting, process optimization, analytical method development, impurity profiling, scale-up engineering, and regulatory support under coordinated quality systems.

A major shift is the growing need for geographically diversified API manufacturing networks. Recent global disruptions exposed vulnerabilities in single-source supply chains, leading sponsors to adopt dual sourcing, regionalized production, and stronger supplier qualification programs. In parallel, regulators have intensified scrutiny of cross-contamination controls, cleaning validation, elemental impurities, residual solvents, and nitrosamine-related risk management. These requirements are encouraging investments in high-containment suites, continuous processing, advanced process analytical technologies, digital batch records, and robust environmental controls.

Sustainability is becoming another defining factor. API manufacturing can involve solvent-intensive and energy-intensive processes, and stakeholders are increasingly focused on green chemistry, solvent recovery, waste minimization, and safer reaction pathways. CDMOs that combine regulatory compliance with operational agility, chemistry innovation, and transparent sustainability practices are better positioned to support next-generation pharmaceutical pipelines.

Cumulative Impact of Artificial Intelligence on API CDMO

Artificial intelligence is creating a cumulative impact across the Active Pharmaceutical Ingredients CDMO value chain by strengthening process development, analytical workflows, quality assurance, and supply chain decision-making. AI-enabled tools can support route selection, reaction optimization, impurity prediction, crystallization modeling, and process parameter analysis, helping development teams reduce experimental cycles while improving process understanding. In API manufacturing, machine learning can enhance deviation detection, equipment monitoring, predictive maintenance, and batch trend analysis when implemented within validated data governance frameworks.

The strongest near-term value of AI lies in augmenting scientific and operational decision-making rather than replacing established GMP controls. AI-assisted literature mining, retrosynthetic analysis, and digital knowledge management can help chemists identify feasible synthetic routes, assess raw material risks, and compare process alternatives. In quality operations, AI can support review-by-exception models, anomaly detection, document intelligence, and faster identification of recurring deviation patterns, provided that data integrity, audit trails, model validation, and human oversight are maintained.

AI adoption also introduces compliance and cybersecurity considerations. CDMOs must ensure that AI systems used in GMP or GMP-adjacent activities are explainable, validated where required, protected against data leakage, and aligned with evolving regulatory expectations for computerized systems. The cumulative effect is a more data-driven API CDMO model in which digital maturity, structured datasets, and cross-functional governance become competitive necessities.

Key Regional Insights Across the API CDMO Ecosystem

Asia-Pacific plays a critical role in the Active Pharmaceutical Ingredients CDMO ecosystem due to its established chemical synthesis capabilities, large supplier base, skilled technical workforce, and significant participation in both generic and innovative drug manufacturing. China and India remain key API production hubs, while Japan, South Korea, Australia, and ASEAN economies contribute through high-quality manufacturing, specialty technologies, clinical supply capabilities, and regional diversification strategies. Regulatory modernization, investment in high-potency handling, and increasing focus on quality systems are strengthening the region's position, although sponsors continue to assess geopolitical risk, environmental compliance, and supply chain transparency.

Europe remains a high-value API CDMO region supported by mature GMP standards, strong chemical engineering expertise, advanced environmental controls, and deep experience with regulated market supply. The region is particularly relevant for specialty APIs, high-potency compounds, complex synthesis, controlled substances, and lifecycle management under stringent quality expectations. European authorities also continue to emphasize data integrity, environmental risk management, and secure access to critical medicines, reinforcing the strategic importance of regional API development and manufacturing.

North America is characterized by strong demand for regulatory-compliant API development and manufacturing, particularly for complex small molecules, oncology-related compounds, controlled substances, and clinical-stage pipelines. The United States and Canada benefit from advanced regulatory infrastructure, innovation-driven pharmaceutical development, and growing interest in domestic or nearshore API supply to improve resilience. Latin America, led by Brazil and Mexico, is gaining attention for regional pharmaceutical manufacturing, access to local demand, and potential supply chain diversification, though infrastructure consistency and regulatory harmonization remain important considerations.

The Middle East is gradually building pharmaceutical manufacturing capabilities, supported by healthcare localization strategies, investment diversification, and national industrial development agendas. The region is increasingly relevant for regional supply security, technology transfer partnerships, and selective pharmaceutical production, while complex API synthesis capacity continues to develop. Africa is emerging as a long-term opportunity area as governments, regional bodies, and health agencies emphasize local medicine production, supply security, workforce development, and regulatory capacity building to reduce dependence on imported essential medicines.

Key Group Insights Influencing API CDMO Strategy

NATO member countries, while not a pharmaceutical trade bloc, are increasingly relevant to Active Pharmaceutical Ingredients CDMO strategy because many members are prioritizing secure supply chains for essential medicines, critical raw materials, and healthcare preparedness. This resilience focus supports interest in trusted supplier networks, geographically diversified sourcing, and domestic or allied-region production for APIs that are important to public health and emergency readiness.

G7 countries continue to shape global API CDMO expectations through advanced pharmaceutical innovation, regulatory leadership, high-value clinical pipelines, and rigorous quality standards. Their policy discussions around supply chain security, medicine shortages, data integrity, and sustainable manufacturing influence sourcing strategies across regulated markets. The European Union remains one of the most influential groups for API CDMO activity due to harmonized regulatory frameworks, strong GMP enforcement, environmental standards, and an increasing focus on strategic autonomy in critical medicines and active substances.

BRICS economies are significant to API CDMO dynamics because they include major pharmaceutical manufacturing and demand centers, particularly China, India, and Brazil, alongside countries pursuing broader industrial and healthcare self-sufficiency. These markets influence raw material flows, generic medicine production, and regional API supply strategies. ASEAN is becoming increasingly relevant as pharmaceutical supply chains seek additional manufacturing locations beyond traditional hubs, with member countries improving industrial infrastructure, regulatory coordination, and investment incentives for intermediates, finished dosage integration, and selective API capabilities.

The GCC is advancing healthcare industrialization through localization policies, pharmaceutical manufacturing incentives, and investments in life sciences infrastructure. For API CDMO stakeholders, the region offers potential in strategic partnerships, regional supply security, technology transfer, and specialized manufacturing initiatives, although technical depth in complex API synthesis is still developing. Across these groups, the most important strategic themes are supply resilience, regulatory convergence, quality assurance, and the ability to support complex API development under internationally accepted GMP expectations.

Key Country Insights for Active Pharmaceutical Ingredients CDMO

The United States is a leading demand center for Active Pharmaceutical Ingredients CDMO services, supported by a robust biopharmaceutical pipeline, stringent regulatory expectations, and increasing emphasis on domestic manufacturing resilience. Canada contributes through regulated manufacturing capabilities, clinical development support, and life sciences investment, while Mexico is gaining relevance through nearshoring advantages, proximity to the U.S. market, and expanding pharmaceutical production capacity. Brazil remains Latin America's largest pharmaceutical market and is important for regional manufacturing, public health procurement, and generic medicine supply.

In Europe, the United Kingdom maintains strengths in pharmaceutical research, clinical development, and specialized manufacturing services. Germany is recognized for chemical engineering excellence, advanced manufacturing standards, and high-quality pharmaceutical production, while France supports API and pharmaceutical manufacturing through established industrial capabilities and health-sector policy focus. Italy and Spain are important European manufacturing bases with experience in regulated production, contract manufacturing, and specialty pharmaceutical supply. Russia has emphasized domestic pharmaceutical production and import substitution, although international access, compliance alignment, and geopolitical factors influence its role in global API CDMO networks.

China remains one of the most influential countries in API manufacturing due to its large chemical production ecosystem, supplier depth, and scale of intermediate and API output, while ongoing quality upgrades and environmental enforcement continue to shape operational standards. India is a major global API and generic medicines hub, supported by extensive chemistry expertise, regulatory experience, and policy initiatives to strengthen domestic production of key starting materials and APIs. Japan is associated with high-quality standards, advanced pharmaceutical manufacturing, and specialty innovation, while South Korea is expanding its broader contract development and manufacturing capabilities with increasing attention to complex and high-value pharmaceutical production. Australia offers advantages in clinical supply, regulated manufacturing, and regional access, supported by strong research institutions and quality infrastructure.

Actionable Recommendations for API CDMO Industry Leaders

Industry leaders should prioritize resilient, compliant, and technology-enabled API CDMO strategies. Sponsors should qualify partners based on GMP inspection history, data integrity maturity, process chemistry expertise, containment capabilities, supply continuity planning, environmental health and safety performance, and regulatory documentation quality. Dual-sourcing and regional diversification should be applied strategically to critical APIs, high-risk starting materials, and products with limited supplier redundancy.

CDMOs should invest in advanced analytical capabilities, high-potency infrastructure, digital quality systems, process analytical technology, and structured knowledge management to support increasingly complex development programs. Building expertise in impurity control, nitrosamine risk assessment, crystallization science, continuous improvement, and green chemistry will be essential for long-term competitiveness. Leaders should also strengthen supplier audits, raw material traceability, cybersecurity governance, and business continuity planning.

To capture future opportunities, API CDMO decision-makers should align commercial strategy with therapeutic complexity, regulatory expectations, and sustainability goals. Early collaboration between chemistry, manufacturing, regulatory, and quality teams can reduce development delays and improve tech transfer outcomes. Transparent communication, robust project governance, and measurable quality performance indicators should be embedded into every sponsor-CDMO relationship.

Research Methodology for API CDMO Analysis

The research methodology for analyzing the Active Pharmaceutical Ingredients CDMO landscape should combine verified secondary research, regulatory intelligence, industry documentation, and expert validation. Key sources include publicly available regulatory guidance, GMP inspection frameworks, pharmacopeial standards, government trade and health agency publications, peer-reviewed scientific literature, patent and pipeline indicators, and industry disclosures related to manufacturing capabilities, quality systems, and technology adoption.

A robust methodology evaluates the market through qualitative and evidence-based assessment rather than unsupported estimates. The analysis should examine API types, synthesis complexity, development stage requirements, regulatory compliance factors, regional manufacturing ecosystems, supply chain dependencies, and technology trends such as AI, automation, continuous processing, and digital quality management. Cross-verification across multiple credible sources helps reduce bias and improve reliability.

Primary validation can include structured interviews or expert consultations with professionals in API process development, quality assurance, regulatory affairs, procurement, supply chain management, and pharmaceutical manufacturing operations. Findings should be triangulated to identify consistent patterns, emerging risks, operational best practices, and strategic implications for sponsors and CDMOs.

Conclusion: Strategic Outlook for API CDMO

The Active Pharmaceutical Ingredients CDMO industry is becoming more strategic, technology-driven, and compliance-intensive as pharmaceutical sponsors navigate complex pipelines, supply chain risk, and evolving regulatory expectations. The sector's future direction will be defined by technical specialization, geographic resilience, digital maturity, and the ability to deliver consistent quality from early development through commercial manufacturing.

AI, advanced analytics, green chemistry, and improved quality systems are reshaping how API development and production are managed, while regional and country-level dynamics continue to influence sourcing decisions. Leaders that combine scientific excellence, regulatory discipline, supply continuity, and sustainable manufacturing practices will be best positioned to support the next generation of medicines in an increasingly complex global pharmaceutical environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Active Pharmaceutical Ingredients CDMO Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Synthetic APIs
  • 7.3. Biotech APIs
    • 7.3.1. Proteins
    • 7.3.2. mAbs
    • 7.3.3. Peptides
  • 7.4. Advanced APIs

8. Active Pharmaceutical Ingredients CDMO Market, by API Category

  • 8.1. Introduction
  • 8.2. Generic APIs
  • 8.3. Branded APIs

9. Active Pharmaceutical Ingredients CDMO Market, by Manufacturing Technology

  • 9.1. Introduction
  • 9.2. Biocatalysis
  • 9.3. Fermentation
  • 9.4. Synthetic Chemistry

10. Active Pharmaceutical Ingredients CDMO Market, by Service Portfolio

  • 10.1. Introduction
  • 10.2. Process Development
    • 10.2.1. Route Scouting & Selection
    • 10.2.2. Process Optimization
    • 10.2.3. Scale-Up & Tech Transfer
  • 10.3. Custom Synthesis
    • 10.3.1. Discovery Scale
    • 10.3.2. Non-GMP Scale
    • 10.3.3. GMP Scale
  • 10.4. Clinical Manufacturing
    • 10.4.1. Phase I Supply
    • 10.4.2. Phase II Supply
    • 10.4.3. Phase III Supply
  • 10.5. Commercial Manufacturing
    • 10.5.1. Dedicated Lines
    • 10.5.2. Multi-Purpose Lines
  • 10.6. Analytical & Quality Services
    • 10.6.1. Method Development
    • 10.6.2. Validation & Transfer
    • 10.6.3. Stability Testing
    • 10.6.4. Release Testing
  • 10.7. Regulatory & Documentation Support
    • 10.7.1. CMC Dossier Preparation
    • 10.7.2. Regulatory Filing Support
    • 10.7.3. Audit & Inspection Support

11. Active Pharmaceutical Ingredients CDMO Market, by Development Phase

  • 11.1. Introduction
  • 11.2. Preclinical Development
  • 11.3. Clinical Phase
  • 11.4. Commercial API Manufacturing

12. Active Pharmaceutical Ingredients CDMO Market, by Therapeutic Application

  • 12.1. Introduction
  • 12.2. Oncology
    • 12.2.1. Solid Tumors
    • 12.2.2. Hematological Malignancies
  • 12.3. Cardiovascular
    • 12.3.1. Hypertension
    • 12.3.2. Dyslipidemia
    • 12.3.3. Thrombosis
  • 12.4. Central Nervous System
    • 12.4.1. Psychiatric Disorders
    • 12.4.2. Neurological Disorders
  • 12.5. Infectious Diseases
    • 12.5.1. Bacterial Infections
    • 12.5.2. Viral Infections
    • 12.5.3. Fungal Infections
    • 12.5.4. Parasitic Infections
  • 12.6. Metabolic & Endocrine
    • 12.6.1. Diabetes
    • 12.6.2. Obesity
    • 12.6.3. Thyroid Disorders
  • 12.7. Respiratory
    • 12.7.1. Asthma
    • 12.7.2. Chronic Obstructive Pulmonary Disease
  • 12.8. Autoimmune & Inflammatory
    • 12.8.1. Rheumatology
    • 12.8.2. Dermatologic Autoimmune
    • 12.8.3. Gastrointestinal Autoimmune
  • 12.9. Gastrointestinal
    • 12.9.1. Acid-Related Disorders
    • 12.9.2. Motility Disorders
    • 12.9.3. Inflammatory Bowel Disease
  • 12.10. Dermatology
    • 12.10.1. Psoriasis
    • 12.10.2. Acne & Rosacea
  • 12.11. Ophthalmology
    • 12.11.1. Glaucoma
    • 12.11.2. Retinal Disorders

13. Active Pharmaceutical Ingredients CDMO Market, by End User

  • 13.1. Introduction
  • 13.2. Pharmaceutical Companies
  • 13.3. Biotechnology Companies
  • 13.4. Generic Drug Manufacturers

14. Active Pharmaceutical Ingredients CDMO Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. Europe
  • 14.3. North America
  • 14.4. Africa
  • 14.5. Latin America
  • 14.6. Middle East

15. Active Pharmaceutical Ingredients CDMO Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. ASEAN
  • 15.6. GCC

16. Active Pharmaceutical Ingredients CDMO Market, by Country

  • 16.1. United States
  • 16.2. China
  • 16.3. Germany
  • 16.4. Japan
  • 16.5. India
  • 16.6. United Kingdom
  • 16.7. France
  • 16.8. Canada
  • 16.9. Australia
  • 16.10. Italy
  • 16.11. South Korea
  • 16.12. Russia
  • 16.13. Brazil
  • 16.14. Mexico
  • 16.15. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. 5N Plus Inc.
  • 18.2. A. R. Life Sciences Pvt. Ltd.
  • 18.3. AbbVie Inc.
  • 18.4. abcr GmbH
  • 18.5. Aurobindo Pharma Limited
  • 18.6. BASF SE
  • 18.7. Biocon Limited
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Cambrex Corporation
  • 18.10. Catalent, Inc. by Novo Holdings A/S
  • 18.11. Cipla Limited
  • 18.12. Corden Pharma International GmbH
  • 18.13. Curia Global, Inc.
  • 18.14. Dr. Reddy's Laboratories Ltd.
  • 18.15. Evonik Industries AG
  • 18.16. IOL Chemicals and Pharmaceuticals Limited
  • 18.17. Jungbunzlauer Suisse AG
  • 18.18. Lonza Group Ltd.
  • 18.19. Lupin Limited
  • 18.20. Merck KGaA
  • 18.21. Minafin Group
  • 18.22. Novartis AG
  • 18.23. Olon S.p.A.
  • 18.24. Pfizer Inc.
  • 18.25. Piramal Group
  • 18.26. PMC Group, Inc.
  • 18.27. Polpharma SA
  • 18.28. Recipharm AB
  • 18.29. Samsung Biologics
  • 18.30. SEQENS
  • 18.31. Siegfried AG
  • 18.32. Sterling Pharma Solutions Limited
  • 18.33. Sun Pharmaceutical Industries Limited
  • 18.34. Teva Pharmaceutical Industries Ltd.
  • 18.35. Thermo Fisher Scientific Inc
  • 18.36. Tiefenbacher API + Ingredients GmbH & Co. KG
  • 18.37. WuXi STA

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECH APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECH APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECH APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOCATALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOCATALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOCATALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FERMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FERMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FERMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC CHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ROUTE SCOUTING & SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ROUTE SCOUTING & SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROUTE SCOUTING & SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROCESS OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROCESS OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROCESS OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SCALE-UP & TECH TRANSFER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SCALE-UP & TECH TRANSFER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SCALE-UP & TECH TRANSFER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISCOVERY SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DISCOVERY SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DISCOVERY SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-GMP SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-GMP SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-GMP SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GMP SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GMP SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GMP SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHASE I SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHASE I SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHASE I SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHASE II SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHASE II SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHASE II SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHASE III SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHASE III SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHASE III SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMMERCIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DEDICATED LINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DEDICATED LINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DEDICATED LINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTI-PURPOSE LINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTI-PURPOSE LINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTI-PURPOSE LINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANALYTICAL & QUALITY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANALYTICAL & QUALITY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANALYTICAL & QUALITY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VALIDATION & TRANSFER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VALIDATION & TRANSFER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VALIDATION & TRANSFER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STABILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STABILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STABILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RELEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RELEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RELEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL REGULATORY & DOCUMENTATION SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL REGULATORY & DOCUMENTATION SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL REGULATORY & DOCUMENTATION SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CMC DOSSIER PREPARATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CMC DOSSIER PREPARATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CMC DOSSIER PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL REGULATORY FILING SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL REGULATORY FILING SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL REGULATORY FILING SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUDIT & INSPECTION SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUDIT & INSPECTION SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUDIT & INSPECTION SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLINICAL PHASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLINICAL PHASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICAL PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMMERCIAL API MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMMERCIAL API MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMMERCIAL API MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DYSLIPIDEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL THROMBOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL THROMBOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL THROMBOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL THYROID DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL THYROID DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL THYROID DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DERMATOLOGIC AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL DERMATOLOGIC AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL DERMATOLOGIC AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL MOTILITY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL MOTILITY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL MOTILITY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACNE & ROSACEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL ACNE & ROSACEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACNE & ROSACEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL GLAUCOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL RETINAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL RETINAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL RETINAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH APIS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL & QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGULATORY & DOCUMENTATION SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY METABOLIC & ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH APIS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL & QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGULATORY & DOCUMENTATION SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY METABOLIC & ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH APIS, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL & QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGULATORY & DOCUMENTATION SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 308. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY METABOLIC & ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 312. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 314. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH APIS, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY API CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE PORTFOLIO, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL & QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGULATORY & DOCUMENTATION SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 333. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 334. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 335. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY METABOLIC & ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 336. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 337. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 338. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 339. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 341. AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. LATIN AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH